Novo Nordisk Teams Up with OpenAI: AI Supercharges the Fight Against Obesity
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.
/ 97 items
#NVO↓
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.
FDA Just Approved Foundayo: The Only GLP-1 Weight-Loss Pill You Can Take Anytime, Anywhere
Eli Lilly’s Foundayo (orforglipron) is now FDA-approved — the only GLP-1 pill for weight loss you can take any time of day, with or without food or water. Average 27 lb loss.
Scholar Rock Shares Jump as Apitegromab BLA Resubmitted to FDA for SMA Treatment
Scholar Rock resubmits its BLA for apitegromab to treat SMA. FDA acceptance expected in 30 days, PDUFA target late September 2026.
Lilly Signs $2.75B AI Drug Deal with Hong Kong’s Insilico Medicine
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI biotech Insilico Medicine for a GLP-1 diabetes drug.
Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth
Eli Lilly’s retatrutide delivered up to 2.0% A1C reduction and 16.8% weight loss (36.6 lbs) in its first Phase 3 trial for type 2 diabetes. Analysts call it a key growth driver for Lilly with strong results vs Mounjaro.